Breaking through the oxygen ceiling: Evidence-based strategies for conquering refractory hypoxemia
Year: 2025
Type: article
Abstract: Primary endpoint selectionThis review primarily focuses on mortality as the most clinically meaningful endpoint when evaluating interventions for refractory hypoxemia.While physiological parameters (oxygenation indices, compliance) and process measures (ventilator-free days) provide valuable information about mechanism and potential benefit, mortality remains the gold standard for determining the true clinical impact of novel interventions.For each trial discussed, we highlight whether a statistically significant mortality benefit was demonstrated, allowing clinicians to better understand which interventions have definitively improved survival.Table 1 provides a comprehensive summary of all interventions reviewed, their effect on mortality, and the quality of supporting evidence. EVOLVING LANDSCAPE OF LUNG-PROTECTIVE VENTILATION STRATEGIES Ultra-protective ventilation with extracorporeal supportThe concept of "ultra-protective ventilation" has gained prominence with the integration of extracorporeal membrane oxygenation (ECMO) or extracorporeal carbon dioxide removal (ECCO 2 R) systems.The EOLIA trial (ECMO to Rescue Lung Injury in Severe ARDS), published by Combes et al. [1] in 2018, represented a pivotal study that, while not meeting its primary endpoint of mortality reduction at 60 days, demonstrated important benefits when analyzed with alternative statistical approaches.The primary analysis showed a mortality of 35% in the ECMO group versus 46% in the conventional management group (P = 0.09), which narrowly missed statistical significance.Key clinical takeaway: ECMO should be considered early in severe ARDS patients with a P/F ratio <80 mmHg for >6 h or <50 mmHg for >3 h despite optimal conventional management.Centers should establish protocols for early identification of potential ECMO candidates and develop referral networks with ECMO-capable centers when this capability is not available locally.The high crossover rate (28%) in the EOLIA trial suggests that rescue ECMO for rapidly deteriorating patients may be beneficial.A post-hoc Bayesian analysis of the EOLIA trial data by Goligher et al. (2018) [11] demonstrated a high probability (>95%) of mortality benefit with early ECMO implementation.Their analysis suggested that for every 6 patients treated with ECMO, one additional life could
Source: Lung India
Authors: Shibu Sasidharan, Sunali Nanayakkara, Ritu Grewal, Priyank Dhiman
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4415482501